Thyroid. 2023 Nov 2. doi: 10.1089/thy.2023.0338. Online ahead of print.
ABSTRACT
BACKGROUND: Nasolacrimal duct obstruction (NLDO) is an adverse effect of high dose radioactive iodine (RAI) therapy for thyroid carcinoma. There are currently no established preventive measures. This study assesses whether preservative free artificial tears (PFATs) can decrease the 131I sodium iodide (I-131) activity in the tears of patients following radioactive iodine (RAI) therapy for thyroid carcinoma, and potentially serve as a preventive measure for RAI-associated NLDO.
METHODS: This non-randomized prospective pilot clinical trial recruited contact-lens wearing patients undergoing RAI therapy for thyroid cancer to self-administer PFATs into the right eye for 4 days starting on the day of RAI ingestion. Left eyes were the controls. While wearing contacts, patients self-administered PFATs per the following – Day 1: every 15 minutes for 2 hours, then every 30 minutes until bedtime, Day 2: every hour for at least 12 hours, Day 3: four times a day, and Day 4: two times a day. Contact lenses were changed daily, and all lenses were collected one week later. Levels of I-131 activity were measured by a well counter, decay-corrected, and converted to units of Bequerel (Bq). Statistical analyses were performed to compare the I-131 activities of the experimental and control eyes.
RESULTS: Sixteen eyes of 8 patients treated with an average of 145.7 millicuries (range 108-159) of I-131 for papillary thyroid cancer were included. On Day 1, artificial tears decreased the geometric mean I-131 activity by 26% in the experimental eyes (p=0.008). Artificial tears also decreased the geometric mean area under the curve (AUC) over four days by 23% (p=0.002).
CONCLUSIONS: I-131 is present in the tears following RAI therapy for thyroid carcinoma. Frequent PFATs starting on the day of RAI ingestion may decrease the level of I-131 in the tears. This finding could have implications for lowering the risk of NLDO. Future multi-center clinical trials are needed to determine if the use of artificial tears after RAI therapy may decrease the risk of NLDO.
CLINICAL TRIAL REGISTRATION: NCT04327999.
PMID:37917111 | DOI:10.1089/thy.2023.0338
